Allison King, M.D., M.P.H., Ph.D.

Profile picture
Researcher, Patient Oriented Research Unit
Professor of Pediatrics, Hematology and Oncology
Professor, Education
Professor, Hematology
Professor, Occupational Therapy
Professor, Surgery
Occupational TherapySurgeryHematology and OncologyEducationHematology


Clinical Interests

  • Pediatric hematology and oncology
  • Children and young adults with sickle cell disease with a focus on cognitive outcomes and educational performance
  • Children with central nervous system tumors
  • Late effects of treatment and issues of survivorship


  • BS, Washington University1992
  • MD, University of Missouri1996
  • MPH, Saint Louis University2003
  • PhD, With Distinction, Saint Louis University2015


  • Resident in Pediatrics, St. Louis Children's Hospital and Washington University School of Medicine1996 - 1999
  • Fellow in Pediatrics, Division of Hematology and Oncology, St. Louis Children's Hospital and Washington University School of Medicine2000 - 2003
  • Visiting Fellow, Children's National Medical Center2002 - 2002

Licensure and Board Certification

  • 1996 - PresMO, Physician - Permanent Licensure
  • 1996 - PresAmerican Board of Pediatrics
  • 1998 - PresNational Board of Medical Examiners
  • 2005 - PresPediatric Hematology and Oncology, American Board of Pediatrics

Honors and Awards

  • American Heart Association Post Doctoral Fellowship Award2003 - 2004
  • National Institutes of Health Pediatric Research Loan Repayment Award2003 - 2006
  • Jacob Javits Junior Investigator Award2005 - 2005
  • ASH Clinical Research Training Institute2005 - 2006
  • ASH Scholar Award2009 - 2014
  • Washington University’s Gerry and Bob Virgil Ethic of Service Award2015
  • American Pediatric Society2018
  • Faculty Member, Alpha Omega Alpha2019
  • Outstanding Faculty Mentor Award, Washington University in St. Louis2019

Recent Publications view all (112)

Publication Co-Authors

  1. Strategies to increase access to basic sickle cell disease care in low- and middle-income countries. Expert Rev Hematol. 2022;1-12. PMID:35400264 
  2. Pregnancy Outcomes with Hydroxyurea Use in Women with Sickle Cell Disease. Am J Hematol. 2022. PMID:35142007 
  3. Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team. BMC Res Notes. 2022;15(1):1. PMCID:PMC8725461  PMID:34983646 
  4. Neurocognitive functioning in preschool children with sickle cell disease. Pediatr Blood Cancer. 2021;e29531. PMID:34971013 
  5. Academic Performance of Children With Sickle Cell Disease in the United States: A Meta-Analysis. Front Neurol. 2021;12:786065. PMCID:PMC8711768  PMID:34966350 
  6. Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA. BMJ Open. 2021;11(11):e050880. PMCID:PMC8601067  PMID:34789492 
  7. Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium. PLoS One. 2021;16(10):e0258638. PMCID:PMC8555833  PMID:34714833 
  8. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood. Br J Haematol. 2021;195(2):256-266. PMID:34272726 
  9. Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia. Exp Biol Med (Maywood). 2021;15353702211035778. PMID:34407676 
  10. Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. Am J Hematol. 2021. PMID:34350622 
  11. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Res Protoc. 2021;10(5):e27650. PMID:34018965 
  12. Electronic Health Record-Embedded Individualized Pain Plans for Emergency Department Treatment of Vaso-occlusive Episodes in Adults With Sickle Cell Disease: Protocol for a Preimplementation and Postimplementation Study. JMIR Res Protoc. 2021;10(4):e24818. PMID:33861209 
  13. Pediatric Neurodevelopmental Delays in Children 0 to 5 Years of Age With Sickle Cell Disease: A Systematic Literature Review. J Pediatr Hematol Oncol. 2021;43(3):104-111. PMID:33560086 
  14. Cognitive performance as a predictor of healthcare transition in sickle cell disease. Br J Haematol. 2021;192(6):1082-1091. PMCID:PMC8092972  PMID:33570182 
  15. Activity competence among infants and toddlers with developmental disabilities: Rasch analysis of the Infant Toddler Activity Card Sort (ITACS). J Patient Rep Outcomes. 2021;5(1):14. PMCID:PMC7818375  PMID:33475869 
  16. Brief Screening Measures Identify Risk for Psychological Difficulties Among Children with Sickle Cell Disease. J Clin Psychol Med Settings. 2020;27(4):651-661. PMCID:PMC7047601  PMID:31463865 
  17. Functional Connectivity Decreases with Metabolic Stress in Sickle Cell Disease. Ann Neurol. 2020;88(5):995-1008. PMCID:PMC7592195  PMID:32869335 
  18. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Blood Adv. 2020;4(18):4463-4473. PMCID:PMC7509876  PMID:32941646 
  19. Validation of the fine motor subtest of the Bayley‐III with children with sickle cell disease using Rasch analysis Child Care Health Dev. 2020;46(5):576-584. PMID:32599661 
  20. Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. Am J Hematol. 2020;95(9):1066-1074. PMCID:PMC8141351  PMID:32449965 
  21. A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. Ann Emerg Med. 2020;76(3S):S64-S72. PMCID:PMC7511000  PMID:32928465 
  22. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv. 2020;4(16):3804-3813. PMCID:PMC7448595  PMID:32785684 
  23. Assessments used to measure participation in life activities in individuals with cancer: a scoping review. Support Care Cancer. 2020;28(8):3581-3592. PMID:32285262 
  24. Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. Orphanet J Rare Dis. 2020;15(1):178. PMCID:PMC7341606  PMID:32635939 
  25. A National Measurement Framework to Assess and Improve Sickle Cell Care in 4 US Regions. Public Health Rep. 2020;135(4):442-451. PMCID:PMC7383758  PMID:32639897 
  26. Stress and the Home Environment in Caregivers of Children with Sickle Cell. J Pediatr Psychol. 2020;45(5):521-529. PMID:32232470 
  27. Association between hydroxycarbamide exposure and neurocognitive function in adolescents with sickle cell disease. Br J Haematol. 2020;189(6):1192-1203. PMID:32103506 
  28. Patient and Parent Decision-Making in the Setting of Chemotherapy-Induced Sensorineural Hearing Loss. Ear Hear. 2020;41(6):1684-1691. doi:0.1097/AUD.0000000000000886  PMID:32427742 
  29. Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care. JAMA Netw Open. 2020;3(5):e206016. PMCID:PMC7260622  PMID:32469413 
  30. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554-1588. PMCID:PMC7189278  PMID:32298430 
  31. Impact of gender and caregiving responsibilities on academic success in hematology. Blood Adv. 2020;4(4):755-761. PMCID:PMC7042991  PMID:32097459 
  32. Impact of the affordable care act dependent coverage provision on young adult cancer patient insurance coverage by sociodemographic and economic characteristics. Cancer Causes Control. 2020;31(1):33-42. PMID:31696421 
  33. The Infant Toddler Activity Card Sort: A Caregiver Report Measure of Children's Occupational Engagement in Family Activities and Routines. OTJR (Thorofare N J). 2020;40(1):36-41. PMID:31161868 
  34. End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Adv. 2019;3(23):3982-4001. PMCID:PMC6963237  PMID:31809538 
  35. Responsive Parenting Behaviors and Cognitive Function in Children With Sickle Cell Disease. J Pediatr Psychol. 2019;44(10):1234-1243. PMCID:PMC6823101  PMID:31579920 
  36. Catalyzing Research to Optimize Cancer Survivors' Participation in Work and Life Roles. OTJR (Thorofare N J). 2019;39(4):189-196. PMID:31046601 
  37. Higher executive abilities following a blood transfusion in children and young adults with sickle cell disease. Pediatr Blood Cancer. 2019;66(10):e27899. doi:10.1002/pbc.27899  PMCID:PMC6707832  PMID:31267645 
  38. Information Needs Regarding Cognitive Late Effects of Caregivers of Central Nervous System Tumor Survivors. OTJR (Thorofare N J). 2019;39(3):159-166. PMID:30417736 
  39. Implementation of an educational intervention to optimize self-management and transition readiness in young adults with sickle cell disease. Pediatr Blood Cancer. 2019;66(7):e27722. PMCID:PMC6529244  PMID:30907500 
  40. Increasing Educational Attainment in Adolescents with Sickle Cell Disease. Soc Work Public Health. 2019;1-15. PMID:31258020 
  41. Impacts of the Affordable Care Act Dependent Coverage Provision on Young Adults With Cancer. Am J Prev Med. 2019;56(5):716-726. PMID:30898535 
  42. Adolescent survivors' information needs for transitions to postsecondary education and employment. Pediatr Blood Cancer. 2019;66(4):e27547. PMID:30408306 
  43. Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2019;37(9):731-740. PMCID:PMC6424138  PMID:30730781 
  44. Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. Biol Blood Marrow Transplant. 2019. PMID:30639825 
  45. The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease. Am J Hematol. 2018;93(12):E391-E395. PMCID:PMC6503654  PMID:30203558 
  46. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatr Blood Cancer. 2018;65(9):e27228. PMID:29797644 
  47. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2018;24(7):1313-1321. PMID:29653206 
  48. Specifying sickle cell disease interventions: a study protocol of the Sickle Cell Disease Implementation Consortium (SCDIC). BMC Health Serv Res. 2018;18(1):500. PMCID:PMC6020469  PMID:29945631 
  49. Children with sickle cell disease: the case for developmental screening. Dev Med Child Neurol. 2018;60(5):443-444. PMID:29516469 
  50. Mentoring Program for Young Adults with Sickle Cell Disease. Occup Ther Health Care. 2018;32(2):124-136. PMID:29533685 
  51. Silent cerebral infarct definitions and full-scale IQ loss in children with sickle cell anemia. Neurology. 2018;90(3):e239-e246. PMCID:PMC5772160  PMID:29263226 
  52. Sickle cell disease and implementation science: A partnership to accelerate advances. Pediatr Blood Cancer. 2017;64(11). PMCID:PMC6026013  PMID:28556441 
  53. Treatment of Leukoencephalopathy With Calcifications and Cysts With Bevacizumab. Pediatr Neurol. 2017;71:56-59. PMCID:PMC5949049  PMID:28424147 
  54. Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro Oncol. 2017;19(5):689-698. PMCID:PMC5464442  PMID:28039368 
  55. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017;23(4):552-561. PMID:28065838 
  56. Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database. Cancer. 2017;123(4):682-687. PMID:27861763 
  57. The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology. Blood. 2016;128(25):2881-2885. PMCID:PMC5179335  PMID:27784672 
  58. Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative. Hematology Am Soc Hematol Educ Program. 2016;2016(1):632-639. PMCID:PMC6142474  PMID:27913539 
  59. A pilot study of parent education intervention improves early childhood development among toddlers with sickle cell disease. Pediatr Blood Cancer. 2016;63(12):2131-2138. PMCID:PMC5344022  PMID:27509845 
  60. Feasibility of a Community-Based Sickle Cell Trait Testing and Counseling Program. J Health Dispar Res Pract. 2016;9(3). PMCID:PMC5070660  PMID:27774352 
  61. Community Health Workers as Support for Sickle Cell Care. Am J Prev Med. 2016;51(1 Suppl 1):S87-98. PMCID:PMC4918511  PMID:27320471 
  62. The National Children's Study: Recruitment Outcomes Using an Enhanced Household-Based Approach. Pediatrics. 2016;137 Suppl 4:S219-30. doi:10.1542/peds.2015-4410C  PMID:27251868 
  63. NCCN Guidelines Insights: Survivorship, Version 1.2016. J Natl Compr Canc Netw. 2016;14(6):715-24. PMID:27283164 
  64. Prevalence of Developmental Delay and Contributing Factors Among Children With Sickle Cell Disease. Pediatr Blood Cancer. 2016;63(3):504-10. doi:10.1002/pbc.25838  PMID:26575319 
  65. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015;90(12):1093-8. PMID:26348869 
  66. Association of social-environmental factors with cognitive function in children with sickle cell disease. Child Neuropsychol. 2015;1-18. doi:10.1080/09297049.2015.1111318  PMCID:PMC4867297  PMID:26568287 
  67. Youth with Sickle Cell Disease: Genetic and Sexual Health Education Needs. Am J Health Behav. 2015;39(6):856-65. PMCID:PMC4741381  PMID:26450553 
  68. The Association of Cytokine Levels With Cognitive Function in Children With Sickle Cell Disease and Normal MRI Studies of the Brain. J Child Neurol. 2015;30(10):1349-53. doi:10.1177/0883073814563140  PMCID:PMC4466214  PMID:25512362 
  69. Transition Needs of Adolescents With Sickle Cell Disease. Am J Occup Ther. 2015;69(2):6902350030p1-5. PMCID:PMC4480057  PMID:26122692 
  70. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. Am J Hematol. 2015;90(2):139-43. doi:10.1002/ajh.23877  PMCID:PMC4304929  PMID:25345798 
  71. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014;89(10):E188-92. PMCID:PMC4261188  PMID:25042018 
  72. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014;61(9):1598-602. PMCID:PMC7681788  PMID:24753394 
  73. Survivorship: healthy lifestyles, version 2.2014. J Natl Compr Canc Netw. 2014;12(9):1222-37. PMID:25190692 
  74. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699-710. PMCID:PMC4195437  PMID:25140956 
  75. Survivorship: immunizations and prevention of infections, version 2.2014. J Natl Compr Canc Netw. 2014;12(8):1098-111. PMID:25099442 
  76. Reconsideration of age as a contraindication for curative therapy of sickle cell disease. JAMA. 2014;312(1):33-34. doi:10.1001/jama.2014.7193  PMID:25058214 
  77. Survivorship: cognitive function, version 1.2014. J Natl Compr Canc Netw. 2014;12(7):976-86. PMID:24994918 
  78. Survivorship: fatigue, version 1.2014. J Natl Compr Canc Netw. 2014;12(6):876-87. PMID:24925198 
  79. Social skills and executive function among youth with sickle cell disease: a preliminary investigation. J Pediatr Psychol. 2014;39(5):493-500. doi:10.1093/jpepsy/jst138  PMCID:PMC4027877  PMID:24431467 
  80. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089-94; quiz 3210. doi:10.1182/blood-2013-01-435776  PMID:24511087 
  81. Survivorship: sleep disorders, version 1.2014. J Natl Compr Canc Netw. 2014;12(5):630-42. PMID:24812132 
  82. Survivorship: pain version 1.2014. J Natl Compr Canc Netw. 2014;12(4):488-500. PMID:24717568 
  83. Survivorship: sexual dysfunction (male), version 1.2013. J Natl Compr Canc Netw. 2014;12(3):356-63. PMID:24616541 
  84. Development and feasibility of a home-based education model for families of children with sickle cell disease. BMC Public Health. 2014;14(1):116. doi:10.1186/1471-2458-14-116  PMID:24499305 
  85. Survivorship: sexual dysfunction (female), version 1.2013. J Natl Compr Canc Netw. 2014;12(2):184-92. PMID:24586080 
  86. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014;89(2):162-7. doi:10.1002/ajh.23604  PMID:24123128 
  87. Survivorship: introduction and definition. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12(1):34-45. PMID:24453291 
  88. Moving from gene discovery to clinical trials in Hutchinson-Gilford progeria syndrome. Neurology. 2013;81(5):408-9. doi:10.1212/WNL.0b013e31829d87cd  PMID:23897868 
  89. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012;119(16):3684-90. PMCID:PMC3335377  PMID:22096242 
  90. Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials. 2012;33(2):291-7. PMCID:PMC3577351  PMID:22155024 
  91. Inpatient management of sickle cell pain: a 'snapshot' of current practice. Am J Hematol. 2012;87(3):333-6. PMID:22231150 
  92. Executive function performance on the children's kitchen task assessment with children with sickle cell disease and matched controls. Child Neuropsychol. 2012;18(5):432-48. doi:10.1080/09297049.2011.613813  PMID:21961955 
  93. Oligodendrogliomas in children. J Neurooncol. 2012;106(2):377-82. doi:10.1007/s11060-011-0674-6  PMID:21842314 
  94. Radiation therapy for pilocytic astrocytomas of childhood. Int J Radiat Oncol Biol Phys. 2011;79(3):829-34. PMID:20421157 
  95. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol. 2010;27(2):69-89. doi:10.3109/08880010903360367  PMID:20201689 
  96. Rehabilitation for survivors of pediatric brain tumors: our work has just begun Future Neurology. 2010;5(1):135-146. doi:  
  97. Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report. Neurology. 2009;73(22):1906-13. doi:10.1212/WNL.0b013e3181c17ea8  PMCID:PMC2788797  PMID:19812380 
  98. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101(13):946-58. doi:10.1093/jnci/djp148  PMCID:PMC2704230  PMID:19535780 
  99. Blood transfusion therapy is feasible in a clinical trial setting in children with sickle cell disease and silent cerebral infarcts. Pediatr Blood Cancer. 2008;50(3):599-602. PMID:17985350 
  100. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 2008;30(2):130-4. doi:10.1097/MPH.0b013e31815d1d83  PMID:18376265 
  101. Need for cognitive rehabilitation for children with sickle cell disease and strokes. Expert Rev Neurother. 2008;8(2):291-6. doi:10.1586/14737175.8.2.291  PMID:18271713 
  102. A pilot randomized education rehabilitation trial is feasible in sickle cell and strokes. Neurology. 2007;68(23):2008-11. doi:10.1212/01.wnl.0000264421.24415.16  PMID:17548550 
  103. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology. 2006;67(8):1509-12. PMID:17060590 
  104. Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. J Pediatr Hematol Oncol. 2006;28(7):450-3. PMID:16825992 
  105. A multidisciplinary health care team's efforts to improve educational attainment in children with sickle-cell anemia and cerebral infarcts. J Sch Health. 2006;76(1):33-7. doi:10.1111/j.1746-1561.2006.00064.x  PMID:16457683 
  106. An education program to increase teacher knowledge about sickle cell disease. J Sch Health. 2005;75(1):11-4. PMID:15776876 
  107. Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol. 2003;4(12):769-71. PMID:14662434 
  108. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A. 2003;122A(2):95-9. PMID:12955759 
  109. Inadequate recognition of education resources required for high-risk students with sickle cell disease. Arch Pediatr Adolesc Med. 2003;157(1):104. PMID:12517203 
  110. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet. 2000;93(5):388-92. PMID:10951462 
  111. Hypoglycemia in Beckwith-Wiedemann syndrome. Semin Perinatol. 2000;24(2):164-71. PMID:10805171 
  112. The question of familial meningiomas and schwannomas: NF2B or not to be? Neurology. 2000;54(1):4-5. PMID:10636116 
Last updated: 04/13/2022
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130